Impact of Sarcopenia on Dyspnea in Patients With Asthma
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Clermont-Ferrand
About this trial
Dyspnea in asthma, is mainly due to airway obstruction but can be caused by several alternative diagnoses.
The impact of sarcopenia on dyspnea in patients with asthma is unknown. Sarcopenic asthma had a reduced physical activity and is associated with airway obstruction compared to non-sarcopenic asthma. In patients with obstructive pulmonary disease, sarcopenia is associated with shallow breathing and diverse sensory and affective components of exertional dyspnea .
The morbidity of sarcopenia is also increased by systemic inflammation and the production of inflammatory cytokines as found in inflammatory airway obstruction.
The investigators will investigate the prevalence and impact of sarcopenia in asthmatics patients. This will enable to better manage sarcopenia in asthmatic patients, understand its origins and personalize treatment.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Patient affiliated to a social security scheme.
Patient capable of giving free, informed, written and signed consent.
Asthmatic patients with a diagnosis made by a pulmonologist on GINA level 4 or 5 treatment
Disqualifiers
Patient under guardianship/trusteeship/supervision of justice
Pregnant or breast-feeding women
Unstable heart disease
Patients who have been smoking or have stopped smoking for less than 5 years,
Trial design
Treatments tested in this trial
- muscle evaluation
- Dosage
- Cardiopulmonary exercise test
- Questionnaire and Physical Exam
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov